Wayland Group Corp. Stock Canadian Securities Exchange
Equities
WAYL
CA9442041062
Pharmaceuticals
Sales 2016 | 4.06 5.55 | Sales 2017 | 3.22 4.41 | Capitalization | 203M 278M |
---|---|---|---|---|---|
Net income 2016 | -8M -10.94M | Net income 2017 | -67M -91.59M | EV / Sales 2016 * | - |
Net Debt 2016 | 9.13 12.48 | Net cash position 2017 | 0.42 0.57 | EV / Sales 2017 | 63,046,727 x |
P/E ratio 2016 * |
-
| P/E ratio 2017 |
-2.13
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
Dan Healey
COO | Chief Operating Officer | - | - |
Steven Bennett
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Ben Ward
CEO | Chief Executive Officer | 44 | - |
1st Jan change | Capi. | |
---|---|---|
+40.09% | 6.16B | |
-16.34% | 4.46B | |
-7.11% | 3.27B | |
+5.14% | 3.2B | |
-0.18% | 2.6B | |
+47.93% | 1.98B | |
-7.15% | 1.7B | |
+0.67% | 1.66B | |
-8.73% | 1.61B |